S&P 500   3,121.15 (+0.02%)
DOW   28,018.46 (+0.05%)
QQQ   202.83 (-0.04%)
CGC   14.73 (-3.91%)
GE   11.36 (-1.39%)
ACB   2.42 (-11.36%)
F   8.96 (+0.11%)
BAC   32.95 (+0.06%)
DIS   148.67 (+2.76%)
S&P 500   3,121.15 (+0.02%)
DOW   28,018.46 (+0.05%)
QQQ   202.83 (-0.04%)
CGC   14.73 (-3.91%)
GE   11.36 (-1.39%)
ACB   2.42 (-11.36%)
F   8.96 (+0.11%)
BAC   32.95 (+0.06%)
DIS   148.67 (+2.76%)
S&P 500   3,121.15 (+0.02%)
DOW   28,018.46 (+0.05%)
QQQ   202.83 (-0.04%)
CGC   14.73 (-3.91%)
GE   11.36 (-1.39%)
ACB   2.42 (-11.36%)
F   8.96 (+0.11%)
BAC   32.95 (+0.06%)
DIS   148.67 (+2.76%)
S&P 500   3,121.15 (+0.02%)
DOW   28,018.46 (+0.05%)
QQQ   202.83 (-0.04%)
CGC   14.73 (-3.91%)
GE   11.36 (-1.39%)
ACB   2.42 (-11.36%)
F   8.96 (+0.11%)
BAC   32.95 (+0.06%)
DIS   148.67 (+2.76%)
Log in

Guardant Health Stock Price, Forecast & Analysis (NASDAQ:GH)

$79.93
-0.08 (-0.10 %)
(As of 11/18/2019 11:59 AM ET)
Today's Range
$78.93
Now: $79.93
$80.65
50-Day Range
$60.29
MA: $66.81
$80.12
52-Week Range
$31.06
Now: $79.93
$112.21
Volume11,255 shs
Average Volume1.13 million shs
Market Capitalization$7.51 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications. It also provides LUNAR-1 for minimal residual disease and recurrence detection in cancer survivors. In addition, the company is developing LUNAR-2 for early detection of cancer in higher risk individuals. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone855-698-8887

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$90.64 million
Book Value$8.68 per share

Profitability

Net Income$-85,060,000.00

Miscellaneous

Employees454
Market Cap$7.51 billion
Next Earnings Date3/10/2020 (Estimated)
OptionableNot Optionable

Receive GH News and Ratings via Email

Sign-up to receive the latest news and ratings for GH and its competitors with MarketBeat's FREE daily newsletter.


Guardant Health (NASDAQ:GH) Frequently Asked Questions

What is Guardant Health's stock symbol?

Guardant Health trades on the NASDAQ under the ticker symbol "GH."

How were Guardant Health's earnings last quarter?

Guardant Health Inc (NASDAQ:GH) issued its quarterly earnings data on Thursday, November, 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.39) by $0.25. The business earned $60.85 million during the quarter, compared to analyst estimates of $45.40 million. Guardant Health had a negative net margin of 40.99% and a negative return on equity of 11.70%. The firm's quarterly revenue was up 180.4% on a year-over-year basis. During the same quarter last year, the business earned ($1.94) EPS. View Guardant Health's Earnings History.

When is Guardant Health's next earnings date?

Guardant Health is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Guardant Health.

What price target have analysts set for GH?

5 brokerages have issued 1 year target prices for Guardant Health's stock. Their forecasts range from $84.00 to $135.00. On average, they expect Guardant Health's share price to reach $113.50 in the next year. This suggests a possible upside of 42.7% from the stock's current price. View Analyst Price Targets for Guardant Health.

What is the consensus analysts' recommendation for Guardant Health?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Guardant Health in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Guardant Health.

Has Guardant Health been receiving favorable news coverage?

Media coverage about GH stock has trended very negative recently, InfoTrie reports. The research firm scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Guardant Health earned a news sentiment score of -3.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Guardant Health.

Are investors shorting Guardant Health?

Guardant Health saw a increase in short interest during the month of October. As of October 31st, there was short interest totalling 4,260,000 shares, an increase of 36.1% from the September 30th total of 3,130,000 shares. Based on an average daily volume of 1,290,000 shares, the days-to-cover ratio is currently 3.3 days. Approximately 9.4% of the shares of the company are short sold. View Guardant Health's Current Options Chain.

Who are some of Guardant Health's key competitors?

What other stocks do shareholders of Guardant Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Guardant Health investors own include Twilio (TWLO), NVIDIA (NVDA), Okta (OKTA), Trade Desk (TTD), Shopify (SHOP), Alibaba Group (BABA), Square (SQ), Veeva Systems (VEEV), Arista Networks (ANET) and salesforce.com (CRM).

Who are Guardant Health's key executives?

Guardant Health's management team includes the folowing people:
  • Mr. AmirAli Talasaz, Chairman, Pres & COO (Age 40)
  • Dr. Helmy Eltoukhy Ph.D., Co-Founder, CEO & Director (Age 40)
  • Mr. Michael J. Wiley, Chief Legal Officer (Age 44)
  • Mr. Derek A. Bertocci, Chief Financial Officer (Age 65)
  • Dr. Richard B. Lanman, Chief Medical Officer (Age 64)

When did Guardant Health IPO?

(GH) raised $200 million in an initial public offering on Thursday, October 4th 2018. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen, Leerink Partners and William Blair were co-managers.

Who are Guardant Health's major shareholders?

Guardant Health's stock is owned by a number of of institutional and retail investors. Top institutional investors include VK Services LLC (4.99%), Massachusetts Financial Services Co. MA (0.47%), Nikko Asset Management Americas Inc. (0.33%), Westwood Management Corp IL (0.30%), Sumitomo Mitsui Trust Holdings Inc. (0.28%) and Eagle Asset Management Inc. (0.21%). Company insiders that own Guardant Health stock include Amirali Talasaz, Derek A Bertocci, Helmy Eltoukhy, Ian T Clark, Michael J Wiley, Richard B Lanman, Stanley J Meresman, Timothy P Eckersley and Vision Fund (Aiv M1) Softbank. View Institutional Ownership Trends for Guardant Health.

Which major investors are selling Guardant Health stock?

GH stock was sold by a variety of institutional investors in the last quarter, including VK Services LLC, Handelsbanken Fonder AB, Griffin Asset Management Inc., Janney Montgomery Scott LLC, NEXT Financial Group Inc, Steward Partners Investment Advisory LLC, Capital Investment Advisory Services LLC and Cabot Wealth Management Inc.. Company insiders that have sold Guardant Health company stock in the last year include Amirali Talasaz, Derek A Bertocci, Helmy Eltoukhy, Ian T Clark, Michael J Wiley, Richard B Lanman, Stanley J Meresman, Timothy P Eckersley and Vision Fund (Aiv M1) Softbank. View Insider Buying and Selling for Guardant Health.

Which major investors are buying Guardant Health stock?

GH stock was bought by a variety of institutional investors in the last quarter, including Westwood Management Corp IL, Eagle Asset Management Inc., Carillon Tower Advisers Inc., Nikko Asset Management Americas Inc., Railway Pension Investments Ltd, State of Michigan Retirement System, California Public Employees Retirement System and Massachusetts Financial Services Co. MA. View Insider Buying and Selling for Guardant Health.

How do I buy shares of Guardant Health?

Shares of GH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Guardant Health's stock price today?

One share of GH stock can currently be purchased for approximately $79.56.

How big of a company is Guardant Health?

Guardant Health has a market capitalization of $7.47 billion and generates $90.64 million in revenue each year. The company earns $-85,060,000.00 in net income (profit) each year or ($2.80) on an earnings per share basis. Guardant Health employs 454 workers across the globe.View Additional Information About Guardant Health.

What is Guardant Health's official website?

The official website for Guardant Health is http://www.guardanthealth.com/.

How can I contact Guardant Health?

Guardant Health's mailing address is 505 PENOBSCOT DR., REDWOOD CITY CA, 94063. The company can be reached via phone at 855-698-8887.


MarketBeat Community Rating for Guardant Health (NASDAQ GH)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  139 (Vote Outperform)
Underperform Votes:  120 (Vote Underperform)
Total Votes:  259
MarketBeat's community ratings are surveys of what our community members think about Guardant Health and other stocks. Vote "Outperform" if you believe GH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/18/2019 by MarketBeat.com Staff

Featured Article: Penny Stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel